Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Abstract: The present invention provides a method of quantification of a target nucleic acid, using at least any two of the genes SYT10, EPHA3, PLEKHF1 and KBTBD4 as control genes. In particular, the combination of the genes SYT10, EPHA3, PLEKHF1 and KBTBD4, known as the 4Plex, is provided as a control for nucleic acid quantification. The 4Plex has particular utility as a control for nucleic acid quantification by methylation-specific droplet digital PCR.

Abstract: In some embodiments, the present invention provides chromatin immunoprecipitation (ChIP) methods. In particular, the present invention provides methods and compositions for performing ChIP (e.g., ChlP-seq) assays on small numbers or cells.

Abstract: The present invention provides a method of treating ALK-negative/LTK-positive cancer in a subject, comprising administering to the subject a pharmaceutically-effective dose of a linear inhibitor of ALK. The invention is of particular utility in treating multiple myeloma, including proteasome inhibitor-resistant multiple myeloma.

Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.

Abstract: The present invention relates to CTL peptide epitopes, high-throughput methods for their identification, and their uses. In particular, the present invention relates to peptide epitopes for cancer immunotherapy and Hepatitis C Virus vaccines. The present invention also relates to methods and systems for identifying antigen-specific CTLs.

Abstract: The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.

Abstract: A machine learning algorithm is trained on a number of microscopic images and a measure of outcome of each image. Each image is divided into tiles. The measure of outcome is assigned to each tile of the image. The tiles are then used to train the machine learning algorithm. The trained algorithm may then be used to evaluate images.

Abstract: Aspects of the disclosure relate generally to computer software and musical gameplay elements. More specifically, aspects of the disclosure provide a method of using multiple musical tracks of varying intensity based on well-timed user inputs and/or player advancement in a rhythm-based video game. Other aspects of the disclosure relate to techniques to improve player on beat inputs in a rhythm-based video game.

Abstract: The present disclosure provides a method and an apparatus for producing astatine-211 from alpha-particle bombardment of bismuth-209. The disclosure also relates to a method and apparatus of producing other radionuclides from target nuclides. The apparatus includes a plate having a recessed portion. The recessed portion has a generally inert surface of ceramic or metal, preferably aluminium oxide that does not react with molten bismuth. A bismuth target is placed in the recessed portion and held therein by a foil cover. The foil has a melting temperature greater than target nuclide (i.e., for bismuth, >271° C.). The foil and target nuclide are held in the recessed portion by a cover that is fastened over the foil. The cover has an aperture to allow a beam of radiation, such as alpha particles, from a cyclotron or other accelerator to pass through the cover to the foil and target nuclide.

Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.

Abstract: The present invention relates to cancer immunotherapy. In particular, provided herein are fusion proteins for targeting tumor associated macrophages with immunostimulatory agents.

Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.

Abstract: Dynamic contrast enhanced MRI data and dynamic susceptibility contrast MRI data for a volume of the patient's body including a tumor are used in order to identify the risk of lymph node metastasis. A volume of interest enclosing the tumor is identified and the MRI data for the volume of interest is processed in order to identify one or more parameters relating to the transverse relaxation rate and/or to dynamic changes in the transverse relaxation rate. A comparison is made to previously obtained similar parameters for other patients having similar tumors that are either known to exhibit lymph node metastasis or are known not to exhibit lymph node metastasis in order to determine if the MRI data indicates that the patient has a tumor at greater risk of exhibiting lymph node metastasis or a tumor with a lesser risk of exhibiting lymph node metastasis.

Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosine (5hmC) and/or 5-methylcytosine (5meC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC and/or 5meC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: The present invention relates to a method of identifying or monitoring circulatory failure in a subject, which method comprises assessing the subject's microcirculation in respect of the following parameters: (a) functional capillary density (FCD); (b) heterogeneity of the FCD; (c) capillary flow velocity; (d) heterogeneity of capillary flow velocity; (e) oxygen saturation of microvascular erythrocytes (SmvO2); and (f) heterogeneity of SmvO2; wherein parameters (a) to (d) are assessed visually by microscopy and parameters (e) and (f) are assessed by diffuse reflectance spectroscopy (DRS); well as apparatus and software designed for performance of such a method.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.

Abstract: The invention generally relates to the field of saxitoxins and the identification of microorganisms capable of producing them. More specifically, the invention relates to the identification of genes encoding saxitoxin in dinoflagellates, and methods for the specific detection of dinoflagellates that are producers of saxitoxins.

Abstract: A method for the formation of lithium includes a layer on a substrate using an atomic layer deposition method. The method includes the sequential pulsing of a lithium precursor through a reaction chamber for deposition upon a substrate. Using further oxidizing pulses and or other metal containing precursor pulses, an electrolyte suitable for use in thin film batteries may be manufactured.